166,148 Shares in Kymera Therapeutics, Inc. $KYMR Bought by Eagle Health Investments LP

Eagle Health Investments LP purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 2nd quarter, HoldingsChannel reports. The fund purchased 166,148 shares of the company’s stock, valued at approximately $19,052,000. Kymera Therapeutics accounts for approximately 3.2% of Eagle Health Investments LP’s holdings, making the stock its 14th biggest holding.

Several other large investors have also recently added to or reduced their stakes in the stock. Merck & Co. Inc. acquired a new position in shares of Kymera Therapeutics during the second quarter worth about $88,544,161,000. BlackRock Inc. purchased a new stake in shares of Kymera Therapeutics in the second quarter worth about $635,067,000. Deutsche Bank AG acquired a new stake in shares of Kymera Therapeutics in the second quarter valued at about $12,161,000. TimesSquare Capital Management LLC purchased a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at about $18,041,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at about $24,721,000.

Kymera Therapeutics Trading Up 4.9%

KYMR stock opened at $127.31 on Thursday. Kymera Therapeutics, Inc. has a twelve month low of $39.84 and a twelve month high of $130.05. The company has a market capitalization of $10.59 billion, a P/E ratio of -39.29 and a beta of 1.95. The firm has a 50 day simple moving average of $107.98 and a 200-day simple moving average of $91.49.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.09. The firm had revenue of $65.00 million for the quarter, compared to analysts’ expectations of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm’s quarterly revenue was up 465.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.95) earnings per share. On average, research analysts predict that Kymera Therapeutics, Inc. will post -3.75 EPS for the current year.

Wall Street Analyst Weigh In

KYMR has been the topic of several recent research reports. Citigroup reissued a “buy” rating on shares of Kymera Therapeutics in a research report on Thursday, August 6th. Morgan Stanley reiterated an “overweight” rating and set a $135.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, August 6th. Barclays boosted their target price on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Mizuho upped their target price on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, July 16th. Finally, Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Twenty investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $125.65.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the sale, the director owned 240,123 shares in the company, valued at $25,573,099.50. This represents a 86.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Bruce Booth sold 467,878 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $110.29, for a total value of $51,602,264.62. Following the transaction, the director directly owned 472,267 shares in the company, valued at approximately $52,086,327.43. This represents a 49.77% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 3,604,813 shares of company stock worth $387,557,004. 15.98% of the stock is currently owned by company insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.